WO2002074238A3 - Water soluble and palatable complexes - Google Patents

Water soluble and palatable complexes Download PDF

Info

Publication number
WO2002074238A3
WO2002074238A3 PCT/US2002/003816 US0203816W WO02074238A3 WO 2002074238 A3 WO2002074238 A3 WO 2002074238A3 US 0203816 W US0203816 W US 0203816W WO 02074238 A3 WO02074238 A3 WO 02074238A3
Authority
WO
WIPO (PCT)
Prior art keywords
complexes
water soluble
palatable
methods
active agents
Prior art date
Application number
PCT/US2002/003816
Other languages
French (fr)
Other versions
WO2002074238A2 (en
Inventor
Li-Lan H Chen
Li Tao
Alfred Liang
Original Assignee
Lavipharm Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lavipharm Lab Inc filed Critical Lavipharm Lab Inc
Priority to AU2002242138A priority Critical patent/AU2002242138A1/en
Priority to EP02707749A priority patent/EP1367999A4/en
Priority to JP2002572949A priority patent/JP2004522802A/en
Publication of WO2002074238A2 publication Critical patent/WO2002074238A2/en
Publication of WO2002074238A3 publication Critical patent/WO2002074238A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The products and methods of the present invention provide a means for increasing the solubility and bioavailability of active agents as described in Figure 1. More particularly the invention provides compositions containing active agents as water-soluble complexes with glycyrrhizin, and methods of preparing such complexes. The invention further provides methods for the preparation of highly water soluble complex dosage forms.
PCT/US2002/003816 2001-02-16 2002-02-08 Water soluble and palatable complexes WO2002074238A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2002242138A AU2002242138A1 (en) 2001-02-16 2002-02-08 Water soluble and palatable complexes
EP02707749A EP1367999A4 (en) 2001-02-16 2002-02-08 Water soluble and palatable complexes
JP2002572949A JP2004522802A (en) 2001-02-16 2002-02-08 Water-soluble and savory complex

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26978501P 2001-02-16 2001-02-16
US60/269,785 2001-02-16

Publications (2)

Publication Number Publication Date
WO2002074238A2 WO2002074238A2 (en) 2002-09-26
WO2002074238A3 true WO2002074238A3 (en) 2003-04-10

Family

ID=23028646

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/003816 WO2002074238A2 (en) 2001-02-16 2002-02-08 Water soluble and palatable complexes

Country Status (5)

Country Link
US (1) US7125564B2 (en)
EP (1) EP1367999A4 (en)
JP (1) JP2004522802A (en)
AU (1) AU2002242138A1 (en)
WO (1) WO2002074238A2 (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6726928B2 (en) * 1994-10-28 2004-04-27 R.P. Scherer Technologies, Inc. Process for preparing solid dosage forms for unpalatable pharmaceuticals
GB0119467D0 (en) * 2001-08-09 2001-10-03 Smithkline Beecham Plc Novel compound
EP1414408B1 (en) * 2001-08-09 2006-03-29 Smithkline Beecham Plc Composition comprising paroxetine and a pharmaceutically acceptable glycyrrhizinate salt
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20060039958A1 (en) * 2003-05-28 2006-02-23 Monosolrx, Llc. Multi-layer films having uniform content
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
AU2003224890A1 (en) * 2002-04-08 2003-10-27 Lavipharm Laboratories Inc. Drug-complex microparticles and methods of making/using same
ITMI20020773A1 (en) * 2002-04-11 2003-10-13 Nicox Sa DRUGS FOR THE TREATMENT OF ARTHRITIS
CA2534259C (en) * 2003-08-12 2012-04-24 Nippon Zoki Pharmaceutical Co., Ltd. Glycyrrhizin high-concentration preparation
US20050089502A1 (en) * 2003-08-21 2005-04-28 Todd Schansberg Effervescent delivery system
AU2004289248B2 (en) 2003-11-07 2012-05-03 U.S. Smokeless Tobacco Company Llc Tobacco compositions
US8627828B2 (en) 2003-11-07 2014-01-14 U.S. Smokeless Tobacco Company Llc Tobacco compositions
US20080234291A1 (en) * 2004-01-21 2008-09-25 Marc Karel Jozef Francois Mitratapide Oral Solution
US20070197602A1 (en) * 2004-02-09 2007-08-23 Hashime Kanazawa Combined pharmaceutical composition
US20050186257A1 (en) * 2004-02-20 2005-08-25 Todd Manegold Dissolvable film and method of manufacture
US20050186256A1 (en) * 2004-02-20 2005-08-25 Dihel Deborah L. Dissolvable film comprising an active ingredient and method of manufacture
US9267167B2 (en) 2004-06-28 2016-02-23 Becton, Dickinson And Company Dissolvable films and methods including the same
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
DK2486942T3 (en) 2004-11-24 2019-01-28 Meda Pharmaceuticals Inc COMPOSITIONS CONTAINING AZELASTINE AND PROCEDURES FOR USING IT
CA2621263A1 (en) * 2005-09-09 2007-03-15 Garry L. Myers Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
JP5507840B2 (en) * 2005-09-19 2014-05-28 ユニバーシティ・オブ・ザ・ウィットウォータースランド・ヨハネスブルグ Oral mucosa pharmaceutical dosage form
US20100273844A1 (en) * 2005-09-28 2010-10-28 Oxford Pharmaceutical Services Inc. Pharmaceutical compositions for treating or preventing migaines
US20070141147A1 (en) * 2005-12-21 2007-06-21 Auriga Laboratories, Inc. Sequential release pharmaceutical formulations
US8642016B2 (en) 2006-07-21 2014-02-04 Jsrnti, Llc Medicinal delivery system, and related methods
US20080064694A1 (en) * 2006-09-11 2008-03-13 Auriga Laboratories, Inc. Multi-Phase Release Methscopolamine Compositions
US20080069874A1 (en) * 2006-09-15 2008-03-20 Auriga Laboratories, Inc. Kits for Prevention and Treatment of Rhinitis
FR2906140B1 (en) * 2006-09-22 2008-12-05 Philippe Perovitch GALENIC FORM FOR TRANSMUCOSUS ADMINISTRATION OF ACTIVE INGREDIENTS
US20080085312A1 (en) * 2006-10-04 2008-04-10 Auriga Laboratories, Inc. Multi-Phase Release Potassium Guaiacolsulfonate Compositions
US20080187589A1 (en) * 2007-02-05 2008-08-07 Pinney John M Multi-modal delivery via transmucosal and gastro-intestinal absorption of antihistamines and symptom relief
US8568777B2 (en) * 2007-03-30 2013-10-29 Monosol Rx, Llc Packaged film dosage unit containing a complexate
KR20140088236A (en) 2009-10-01 2014-07-09 앱탈리스 파마테크, 인코포레이티드 Orally administered corticosteroid compositions
JP2012031164A (en) * 2010-07-06 2012-02-16 Teika Seiyaku Kk Film-shaped preparation
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
EP2742350B1 (en) 2011-08-08 2019-10-30 The Coca-Cola Company Cell lines comprising endogenous taste receptors and their uses
US10806703B2 (en) * 2012-01-20 2020-10-20 Lts Lohmann Therapie-System Ag Transmucosal administration system for a pharmaceutical drug
WO2013115744A1 (en) * 2012-01-31 2013-08-08 Mahmut Bilgic A process for production of pharmaceutical (effervescent) composition comprising alpha - glucosidase inhibitor (e.g. vogliobose and metformin)
WO2013115745A1 (en) * 2012-01-31 2013-08-08 Mahmut Bilgic A process for production of pharmaceutical (effervescent) composition comprising alpha - glucosidase inhibitor (e.g. vogliobose and metformin)
US10149850B2 (en) 2013-03-15 2018-12-11 Altria Client Services Llc Oral energy products including encapsulated caffeine
WO2015070049A1 (en) * 2013-11-08 2015-05-14 Insys Pharma, Inc. Sildenafil sublingual spray formulation
CN103601787B (en) * 2013-12-12 2015-10-28 海南育奇药业有限公司 A kind of glycyrrhizin derivative and synthetic method thereof
JP6868972B2 (en) * 2015-06-01 2021-05-12 ロート製薬株式会社 Anti-allergic composition
US11510859B2 (en) 2015-07-16 2022-11-29 Marinomed Biotech Ag Method for improving aqueous solubility of water-insoluble or slightly water-soluble drugs
DK3324933T3 (en) * 2015-07-16 2021-01-18 Marinomed Biotech Ag METHOD OF IMPROVING WATER SOLUBILITY OF WATER-SOLUBLE OR WEAK WATER-SOLUBLE MEDICINES
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
KR20230137362A (en) 2016-05-05 2023-10-04 어퀘스티브 테라퓨틱스, 아이엔씨. Enhanced delivery epinephrine compositions
CN109486907B (en) * 2018-12-21 2022-02-11 陕西师范大学 Loop-mediated isothermal amplification reagent capable of being transported at normal temperature, preparation method and application
WO2022106923A1 (en) 2020-11-18 2022-05-27 BioPharma Synergies, S. L. Orodispersible powder composition comprising an antihistamine compound

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112625A (en) * 1989-02-15 1992-05-12 Wm. Wrigley Jr. Company Aqueous zein coated sweeteners and other ingredients for chewing gum
US6103765A (en) * 1997-07-09 2000-08-15 Androsolutions, Inc. Methods for treating male erectile dysfunction
US6165512A (en) * 1998-10-30 2000-12-26 Fuisz Technologies Ltd. Dosage forms containing taste masked active agents

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB919039A (en) * 1959-12-30 1963-02-20 Biorex Laboratories Ltd Anti-tussive compositions comprising glycyrrhetinic acid and related compounds
US3878192A (en) * 1972-06-05 1975-04-15 Blasina Lab Chim Farm Sweet and palatable water soluble derivatives of erythromycin
US5112804A (en) * 1987-04-01 1992-05-12 Temple University Of The Commonwealth System Of Higher Education Pharmaceutical composition and method of intranasal administration
EP0327756B1 (en) * 1987-11-13 1994-01-26 Smithkline Beecham Farmaceutici S.p.A. Pharmaceutical compositions comprising a calcitonin and a glycyrrhizinate as absorption enhancer
CA2044663A1 (en) * 1990-07-12 1992-01-13 Makoto Tanaka Water-dispersible polyene antifungal complexes
US5576014A (en) * 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US6162459A (en) * 1995-02-24 2000-12-19 National Science Council Acyclovir transdermal delivery system
JPH11246439A (en) * 1998-03-02 1999-09-14 Hisamitsu Pharmaceut Co Inc Transmucosal absorption accelerator
US6541048B2 (en) * 1999-09-02 2003-04-01 Wm. Wrigley Jr. Company Coated chewing gum products containing an acid blocker and process of preparing
AU2001228791A1 (en) * 2000-08-31 2002-03-13 Council Of Scientific And Industrial Research A composition comprising pharmaceutical/nutraceutical agent and a bio-enhancer obtained from glycyrrhiza glabra

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112625A (en) * 1989-02-15 1992-05-12 Wm. Wrigley Jr. Company Aqueous zein coated sweeteners and other ingredients for chewing gum
US6103765A (en) * 1997-07-09 2000-08-15 Androsolutions, Inc. Methods for treating male erectile dysfunction
US6165512A (en) * 1998-10-30 2000-12-26 Fuisz Technologies Ltd. Dosage forms containing taste masked active agents

Also Published As

Publication number Publication date
AU2002242138A1 (en) 2002-10-03
JP2004522802A (en) 2004-07-29
US20020147201A1 (en) 2002-10-10
EP1367999A4 (en) 2007-04-18
EP1367999A2 (en) 2003-12-10
US7125564B2 (en) 2006-10-24
WO2002074238A2 (en) 2002-09-26

Similar Documents

Publication Publication Date Title
WO2002074238A3 (en) Water soluble and palatable complexes
ZA200201511B (en) 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents.
HUP0401982A3 (en) Indolizine derivates, process for their preparation and pharmaceutical compositions containing the compounds
HUP0300207A3 (en) 1,2,3,4-tetrahydroisquinoline derivatives, pharmaceutical compositions containing them and their preparation processes
WO2004050058A3 (en) Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
ZA200301813B (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them.
WO2003035051A3 (en) The use of proton sequestering agents in drug formulations
WO2002080976A3 (en) Hsa-free formulations of interferon-beta
CA2468916A1 (en) A stable oxaliplatin solution formulation
CA2322315A1 (en) Fast disintegrating tablets
IL150539A0 (en) Novel 1,3-dihydro-2h-indol-2-one derivatives, preparation method and pharmaceutical compositions containing them
IL157933A (en) Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions comprising them
HUP0303958A2 (en) Heterocyclyloxy-, thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands, process for their preparation and pharmaceutical compositions containing them
HUP0401292A3 (en) Pyrazolo[1,5-a]pyridines, pharmaceutical compositions containing the same and process for preparation thereof
HUP0402640A3 (en) Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands, process for their preparation and pharmaceutical compositions thereof
HUP0400832A3 (en) New amidoalkyl-piperidine and amidoalkyl-piperazine derivatives, and pharmaceutical compositions containing such derivatives as active ingredients
HUP0300163A3 (en) Clathrate complexes formed by hyaluronic acid derivates, process for their preparation and pharmaceutical compositions containing them and their use
IL154096A0 (en) Aporphine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
IL161631A (en) Soy milk compositions prepared by a process providing improved texture and the process for such a preparation
HUP0302193A3 (en) 1,4-diazabicyclo[3.2.2]nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation thereof and pharmaceutical compositions containing them
ZA200109602B (en) Purine derivatives, preparation method and pharmaceutical compositions containing same.
HUP0304085A3 (en) The citrate salt of 5,8,14-triazatetracyclo(10.3.1.02,11.04,9)-hexadeca-2.(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
EP1291362A4 (en) A complex between folic acid and polysaccharides, its preparation method and a pharmaceutical composition comprising said complex as active component
AP2004003045A0 (en) Preparation compositions containing acid-unstable physiologically active compounds and process for producing the same.
ZA200110150B (en) Streptogramin derivatives, preparation and compositions containing them.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002572949

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002707749

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002707749

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642